Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03252483 · ClinicalTrials.gov registry record · NA
Integrating HIV and Hepatitis C Screening in an Urban Emergency Department
A NA study of HIV and Hepatitis C, sponsored by New York City Health and Hospitals Corporation.
- Completed
- Registry status
- NA
- Development phase
- 478
- Enrollment target
- 1
- Study location
NCT03252483: Completed NA study of HIV and Hepatitis C, sponsored by New York City Health and Hospitals Corporation.
NCT03252483 is a NA study of HIV and Hepatitis C that has completed, run by New York City Health and Hospitals Corporation. The registered enrollment target is 478 participants, roughly in line with the 438-participant average among 303 other HIV trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03252483, a NA study of HIV and Hepatitis C, has completed, sponsored by New York City Health and Hospitals Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 478 participants
- Enrollment target
- 1
- Study location
Study Summary
This randomized controlled trial was implemented to evaluate the effect of integrating rapid Hepatitis C (HCV) testing into a pre-existing screening program for Human Immunodeficiency Virus (HIV) on HIV test acceptance and diagnosis of both HCV and HIV. A sample of 478 adults in a New York City Emergency Department participated in the study. Participants were randomized to receive either an offer of bundled HIV/HCV testing or HIV testing alone. Public Health Advocates approached eligible patients in the Emergency Department, performed HIV and HCV raid testing, and delivered test results to participants with post-test counseling. The primary outcome, HIV test acceptance, was compared between the two groups to evaluate whether the addition of an HCV test adversely impacted participants' consent to test for HIV. Questionnaires were also distributed to participants to assess HCV knowledge.
Primary Outcome
Participant agreement to test for HIV with a rapid Oraquick oral swab
Conditions Studied
Interventions
- OTHER Bundled HCV/HIV Screening
- OTHER HIV Screening
Study Locations (1)
New York
- Jacobi Medical Center - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 478 participants |
| Start Date | 2012-12 |
| Est. Completion | 2013-05 |
| Phase | NA |
What the finished NCT03252483 record still lists
NCT03252483 is an interventional study that assigns participants to a tested intervention. The registered 478 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 438-participant average among 303 other HIV trials with a reported enrollment target.
The record links to 5 conditions, with HIV appearing as the primary indexed condition, and to 2 interventions - of which Bundled HCV/HIV Screening is the first listed.
NCT03252483 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT03252483 about?
NCT03252483 is a clinical study titled "Integrating HIV and Hepatitis C Screening in an Urban Emergency Department". This randomized controlled trial was implemented to evaluate the effect of integrating rapid Hepatitis C (HCV) testing into a pre-existing screening program for Human Immunodeficiency Virus (HIV) on HIV test acceptance and diagnosis of both HCV and HIV. A sample of 478 adults in a New York City Emer...
What is the current status of trial NCT03252483?
This trial is currently completed. It is a NA study. The enrollment target is 478 participants. The study started on 2012-12. Estimated completion is 2013-05.
What conditions does trial NCT03252483 study?
This clinical trial studies the following conditions: HIV, Hepatitis C, HIV/AIDS, HIV/AIDS and Infections, HCV Coinfection.
What interventions are being tested in trial NCT03252483?
The interventions under investigation include: Bundled HCV/HIV Screening (OTHER), HIV Screening (OTHER).
Who is sponsoring clinical trial NCT03252483?
This trial is sponsored by New York City Health and Hospitals Corporation, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03252483 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03252483's enrollment target sits among peer trials
478 36th of 303 higher than 268 of 303 other HIV trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Text Education About Cardiovascular Health and HIV (TEACH-HIV)
RECRUITING · NA
-
1MoreStep: An Intervention to Increase HIV Care Engagement and Reduce Intimate Partner Violence Among Black Women Living With HIV
RECRUITING · NA
-
Implementation Trial to Evaluate a Population Health Combination Intervention to Meet HIV Testing, Linkage, and Viral Suppression Goals in Alabama
RECRUITING · NA
-
ACCESS: Accelerating Cervical Cancer Elimination Through the Integration of Screen-and-treat Services
RECRUITING · NA
-
Assessing Peer Support for Physical Activity in Women With HIV and Hypertension
RECRUITING · NA
-
Open Trial of Trauma-focused Psychodynamic Psychotherapy for People Living With HIV and PTSD
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05446272 · 478 participants · NA
The Diaphragmatic Initiated Ventilatory Assist (DIVA) Trial
- NCT06172296 · 478 participants · Phase 3
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
- NCT04221542 · 479 participants · Phase 1
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
- NCT03911700 · 477 participants · NA
Prophylactic Reinforcement of Ventral Abdominal Incisions Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia